All In Biotech

Drug Trial Radar · NCT07847580

Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions

Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary Interventions: A Prospective, Multi-Center Randomized Trial

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Jun 30, 2029

Study completion Jul 31, 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 45 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the effect of pre-operative dexmedetomidine on periprocedural myocardial injury in patients having percutaneous coronary intervention (PCI). The specific research hypothesis is that intranasal administration of 100 μg dexmedetomidine (DEX) reduces the incidence of periprocedural myocardial injury within 48 hours after PCI, as compared with normal saline. Participants will be randomly assigned in a 1:1 ratio to two groups: the dexmedetomidine group and the placebo group.

Conditions

  • Coronary Heart Disease
  • Coronary Artery Disease

Interventions

  • Intranasal dexmedetomidineDrug

    Patients will receive intranasal DEX (100 μg) 60 ± 10 minutes before the procedure in the preoperative preparation area, with the solution equally sprayed into both nostrils (two sprays per nostril).

  • Normal SalineDrug

    Patients will receive an equal volume of intranasal normal saline containing no active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myocardial injury occurring within 48 hours after surgeryTime frame: Within 48 hours after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.